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Hemopatı́as Malignas) Cooperative Study Group
abstract
PURPOSE Assessing measurable residual disease (MRD) has become standard with many tumors, but the
clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-
generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-
negative criterion defined by the International Myeloma Working Group (IMWG).
PATIENTS AND METHODS In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM
had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexa-
methasone (VRD), autologous transplantation, and two consolidation courses with VRD. MRD was assessed in
1,100 bone marrow samples from 397 patients; the 61 patients without MRD data discontinued treatment
during induction and were considered MRD positive for intent-to-treat analysis. The median limit of detection
achieved by NGF was 2.9 3 1026. Patients received maintenance (lenalidomide 6 ixazomib) according to the
companion PETHEMA/GEM2014MAIN trial.
RESULTS Overall, 205 (45%) of 458 patients had undetectable MRD after consolidation, and only 14 of them
(7%) have experienced progression thus far; seven of these 14 displayed extraosseous plasmacytomas at
diagnosis and/or relapse. Using time-dependent analysis, patients with undetectable MRD had an 82% re-
duction in the risk of progression or death (hazard ratio, 0.18; 95% CI, 0.11 to 0.30; P , .001) and an 88%
reduction in the risk of death (hazard ratio, 0.12; 95% CI, 0.05 to 0.29; P, .001). Timing of undetectable MRD
(after induction v intensification) had no impact on patient survival. Attaining undetectable MRD overcame poor
prognostic features at diagnosis, including high-risk cytogenetics. By contrast, patients with Revised In-
ternational Staging System III status and positive MRD had dismal progression-free and overall survivals
(median, 14 and 17 months, respectively). Maintenance increased the rate of undetectable MRD by 17%.
CONCLUSION The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate
treatment efficacy in MM.
J Clin Oncol 38. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Assessing measurable residual disease (MRD) has
become a standard procedure in many hematologic
malignancies,1-4 but the lack of effective therapies for
multiple myeloma (MM) delayed the interest to per-
formMRD studies in this disease until the past decade.
Although initial data were obtained using low-sensitive
and nonstandardized methods5-19 or with next-
generation sequencing (NGS) applied in retrospec-
tive series of patients treated with older regimens,20,21
depth of response based on MRD emerged as one of
the most relevant prognostic factors in MM.15,22,23
Thus, the International Myeloma Working Group
(IMWG) updated the response criteria in 2016 to foster
standardized assessment of MRD in prospective trials,
which should incorporate MRD-negative definitions
based on NGS, next-generation flow cytometry (NGF),
and positron-emission tomography/computerized to-
mography (PET/CT).24 Thus far, a few studies have
investigated the utility of PET/CT25-30 and NGS27,31-34 in
patients treated with novel regimens, and the im-
pressive results obtained with NGS in five trials31-35
validated the new IMWG sequencing MRD-negative
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using NGF in trials have validated the encouraging pre-
liminary results reported by EuroFlow,36 and many ques-




Assessment of MRD was a secondary end point in the
PETHEMA/GEM2012MENOS65 clinical trial (Appendix,
online only). This open-label, phase III study included 458
patients receiving six induction cycles of bortezomib,
lenalidomide, and dexamethasone (VRD), autologous
stem-cell transplantation (ASCT) conditioned with busulfan
and melphalan (ie, Bu-Mel) or melphalan (ie, Mel-200)
high-dose therapy (HDT), and two consolidation cycles of
VRD (Appendix Fig A1, online only).38 The primary end
point was progression-free survival (PFS) after Bu-Mel
versus Mel-200, and it has not been met yet. Afterward,
patients were enrolled in the PETHEMA/GEM2014MAIN
clinical trial that randomly assigned them to maintenance
with lenalidomide and low-dose dexamethasone (Rd) or Rd
plus ixazomib for 2 years, after which patients continued
with Rd for an additional 3 years if MRD positive or stopped
therapy if MRD negative. Each study site’s independent
ethics committee approved the protocol, and informed
consent forms were required prior to patient enrollment.
Studies were registered at www.clinicaltrials.gov (Clinical-
Trials.gov identifiers: NCT01916252, NCT02406144) and
EudraCT (EudraCT identifiers: 2012-005683-10, 2014-
000554-10), and the studies were conducted per the
ethical principles of the Declaration of Helsinki.
MRD Assessment
MRD was predefined to be assessed at the time of sus-
pected complete remission (CR), after induction, at day
100 after HDT/ASCT, and after consolidation. Of the 458
patients enrolled, 397 had at least one assessment of MRD
performed after one or more of these defined treatment
phases. The 61 patients without assessment of MRD dis-
continued therapy during induction. Another 26 patients
discontinued therapy during intensification. Other reasons
for missing MRD data (n = 52 [4.5%] of 1,152) are de-
scribed in Figure 1. Overall, 377, 352, and 357 patients had
MRD evaluable after induction, HDT/ASCT, and consoli-
dation, respectively. MRD continued to be assessed every
year during maintenance (PETHEMA/GEM2014MAIN),
and data from the first 2 years were analyzed.
MRD was evaluated using NGF developed by EuroFlow
(Appendix, online only).36 The number of viable nucleated
cells was systematically registered, and the limit of de-
tection (LOD) achieved by NGF was determined in each
sample according to the following formula: (20/number of
viable nucleated cells) 3 100. Patients had detectable
MRD whenever the percentage of phenotypically aberrant
clonal plasma cells (PCs) was equal to or greater than the
LOD achieved in the corresponding sample. To determine
the impact of detectable MRD levels on survival, patients
were grouped according to the following MRD logarithmic
levels: $ 2 3 1026 to , 1025, $ 1025 to , 1024, and
$ 1024. Conversely, patients had undetectable MRD when
phenotypically aberrant clonal PCs were either absent or
present at percentages lower than the LOD achieved in the
corresponding sample.
Statistical Analyses
To avoid narrowing the study by considering only those
patients who experienced a response to treatment (ie, fa-
vorable disease course), MRD results were analyzed on the
intent-to-treat population (n = 458) unless otherwise
specified. Thus, patients with active disease who dis-
continued treatment were considered to have detectable
MRD at that moment and thereafter. As expected, these
patients had poor PFS (median, 13 months). Patients
without an assessment of MRD at a specific timepoint for
reasons other than discontinuing treatment also were
considered to have detectable MRD at that timepoint.
The effect of an MRD response was evaluated using Cox
proportional hazards models that considered MRD as
a time-dependent covariable; all patients had disease at
diagnosis (time = 0), and their MRD statuses were updated
after induction (time = 1), HDT/ASCT (time = 2), and
consolidation (time = 3). The effect of MRD conversions
during maintenance was not included because of short
follow-up. Cox regression models for PFS and overall
survival (OS) were adjusted for sex, age, International
Staging System (ISS), serum lactate dehydrogenase (LDH)
levels, and fluorescence in situ hybridization cytogenetics;
high-risk cytogenetics was defined by the presence of
t(4;14), t(14;16) and/or del(17p) alterations. The re-
gression models were performed by entering an interaction
term between patient subgroup and MRD status.
Survival probabilities according to persistent versus un-
detectable MRD after consolidation were estimated using
the Kaplan-Meier method. Briefly, differences were tested
for statistical significance with the (two-sided) log-rank test,
and hazard ratios (HRs; with two-sided 95% CIs) were
estimated with a Cox regression model. PFS was defined as
the time fromMRD assessment until disease progression or
death of any cause, and OS was defined as the time from
MRD assessment until death. To estimate survival proba-
bilities in all patients stratified at diagnosis by the Revised
ISS (R-ISS; n = 404), PFS was defined as the time from
study entrance until disease progression or death of any
cause, and OS was defined as the time from study entrance
until death. Multivariable Cox regression models with for-
ward selection were performed to evaluate, at each step,
the prognostic value of risk stratification at diagnosis based
on the R-ISS and after treatment based on MRD status.
Variables were introduced in the models if P was , .05.
Statistical analyses were conducted using SAS (SAS
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Institute, Cary, NC), STATA (version 15.0; StataCorp,
College Station, TX), and Statistical Package for Social
Sciences (version 20.0; SPSS, Chicago, IL).
RESULTS
Applicability and Sensitivity of NGF
A total of 1,119 bone marrow (BM) aspirates were tested
after induction, HDT/ASCT, or consolidation, and evaluable
data were obtained from 1,114 aspirates (99.6%). NGF
was unsuccessful in five samples (0.4%) because of in-
adequate specimen processing and/or instrument setup.
The percentages of B-cell precursors, nucleated red blood
cells, and mast cells were evaluated in each sample
to determine the extent of hemodilution. Samples with
, 0.01% BM PCs, B-cell precursors, nucleated red blood
cells, and mast cells (n = 14 of 1,114) were considered
severely hemodiluted and inadequate for MRD assess-
ment. The median LOD achieved by NGF in the 1,100 BM
aspirates evaluable for MRD was 2.9 3 1026 (range, 1 3
1026 to 1.14 3 1024). The logarithmic ranges of , 2 3
1026, 2 3 1026 to , 1025, $ 1025 to , 1024, and $ 1024
were achieved in 11 (1%), 965 (88%), 1,099 (99.9%), and
1,100 samples (100%), respectively.
Rates of Undetectable MRD With VRD Induction, HDT/
ASCT, and VRD Consolidation
In the intent-to-treat population (n = 458), 129 (28%), 194
(42%), and 208 (45%) patients had undetectable MRD
after induction, HDT/ASCT, and consolidation, respectively.
After consolidation, 34% of patients had MRD levels
$ 1024, 10% had levels of$ 1025 to, 1024, and 11% had
levels of $ 2 3 1026 to , 1025.
Despite similar rates of undetectable MRD after HDT/ASCT
and consolidation, a detailed analysis of MRD log levels
among patients with persistent MRD showed that 8% had
MRD levels in the logarithmic range of 2 3 1026 to , 1025
after HDT/ASCT, but subsequent consolidation reduced
Patients enrolled
(N = 458) 
Patients discontinued during induction
Due to progression/relapse         
 Patients evaluable for response assessment after induction                   (n = 397)
Patients had evaluable MRD                                                          (n = 377) 
Patients with missing MRD data                                        (n = 20) 
Patients discontinued during transplant     (n = 13)
Due to progression/relapse                         (n = 5)
Patients evaluable for response assessment after transplant                   (n = 384) 
Patients had evaluable MRD                                                         (n = 352) 
Patients with missing MRD data                                       (n = 32) 
    Due to investigator decision                                                                (n = 1) 
    Patients withdrew consent to BM aspiration                                (n = 1)
    BM aspirates not sent to central laboratory                                     (n = 13) 
    Due to test failure                                                                                 (n = 1)
    Due to hemodilution of BM aspirates                                                 (n = 4)
    Due to investigator decision                                                                (n = 3) 
    BM aspirates not sent to central laboratory                                    (n = 21) 
    Due to test failure                                                                                            (n = 2) 
    Due to hemodilution of BM aspirates                                                (n = 6) 
Patients discontinued during consolidation  (n = 13)
   Due to progression/relapse                             (n = 4)
Patients evaluable for response assessment after consolidation             (n = 371) 
Patients had evaluable MRD                                                        (n = 357) 
Patients with missing MRD data                                        (n = 14) 
    Due to investigator decision                                                               (n = 1) 
    BM aspirates not sent to central laboratory                                      (n = 6) 
    Due to severe delay in sample shipment                                         (n = 1)
    Due to test failure                                                                                                                             (n = 2)
    Due to hemodilution of BM aspirates                                                                                            (n = 4) 
(n = 61)
 (n = 34)
FIG 1. Patient disposition and mea-
surable residual disease (MRD) as-
sessments in the GEM2012MENOS65
clinical trial. BM, bone marrow.
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MRD levels to a range of 23 1026 to, 1025 in 19% of MRD-
positive patient cases (Appendix Table A1, online only).
Patient MRD statuses according to conventional response
criteria are listed in Appendix Table A2 (online only). Of
note, all patients in partial response or less and un-
detectable MRD after induction remained MRD negative in
subsequent timepoints, and all but two reached CR.
Similarly, 32 of the 33 patients with very good partial re-
sponse and undetectable MRD after induction remained
MRD negative, and 18 reached CR.
Characteristics of Patients Who Experienced Disease
Progression Despite Undetectable MRD
With a median follow-up of 40 months, disease progression
occurred in 14 patients (7%) with undetectable MRD
versus 101 patients (40%) with persistent MRD after
consolidation (P , .001). Appendix Table A3 (online only)
lists the characteristics of patients who experienced pro-
gression despite an undetectable MRD: five of 14 displayed
ISS-III status, four of 14 had high LDH levels, and only two
of 14 had high-risk cytogenetic abnormalities. More than
half of the patients were early responders with negative
MRD after induction (eight of 14). Interestingly, many
patients experienced relapse without detectable M-protein
(nine of 14) or BM infiltration (seven of 14) and with
extraosseous plasmacytomas (six of 14); in fact, these traits
were already observed in five of these patients at diagnosis.
Risk of Disease Progression in Patients With Persistent
Versus Undetectable MRD
Using a Cox proportional hazards model in which the
patient’s MRD status was treated as a continuous time-
dependent variable, we found that achieving undetectable
MRD before maintenance was associated with an 82%
reduction in the risk of progression or death (HR, 0.18;
95% CI, 0.11 to 0.30; P , .001) and an 88% reduction in
the risk of death (HR, 0.12; 95% CI, 0.05 to 0.29;
P , .001).
Using MRD as a fixed covariable, the Kaplan-Meier esti-
mate of the 36-month PFS rate was 87% versus 50% in
patients with undetectable versus persistent MRD after
consolidation (Fig 2A). The 36-month OS rate was 96%
versus 88% in patients with undetectable versus persistent
MRD (Fig 2B). Data on time to progression and cumulative
incidence of relapse are shown in Appendix Fig A2 (online
only). The HRs for PFS and OS according to patient MRD
statuses after consolidation were 0.21 (95% CI, 0.12 to
0.36; P, .001) and 0.26 (95% CI, 0.10 to 0.67; P = .005),
respectively. The effect of MRD in reducing the risk of
progression or death was independent of treatment arm
(Appendix Tables A4 and A5, online only) and of whether
patients were in CR (Appendix Fig A3, online only) or in less
than CR (HR, 0.10; 95% CI, 0.01 to 0.72; P = .02). By
contrast, there were no significant differences in PFS
(P = .21) and OS (P = .60) in patients with positive MRD in
CR versus less than CR after consolidation.
Positive MRD in the Logarithmic Range of ‡ 2 3 1026 to
< 1025 Is Clinically Relevant
Among patients with persistent MRD, there were no sig-
nificant differences in PFS according to the logarithmic
range of MRD levels (ie, $ 2 3 1026 to , 1025, $ 1025 to
, 1024, and$ 1024). Thus, even patients who had very low
but positive MRD levels in the logarithmic range of $ 2 3
1026 to , 1025 displayed significantly inferior PFS
(P , .001) and a trend for inferior OS (P = .07) compared
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FIG 2. Survival according to undetectable v persistent measurable residual disease (MRD). The Kaplan-Meier estimates of (A) progression-free
survival (PFS) and (B) overall survival (OS) after MRD assessment after consolidation (n = 357). HR, hazard ratio.
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Undetectable MRD Is of Similar Significance at
Distinct Timepoints
There were no significant differences in survival between
patients with undetectable MRD achieved after induction or
after treatment intensification (ie, HDT/ASCT and/or con-
solidation). The 36-month rates of PFS were 88% and 85%
(P = .38), respectively, whereas the 36-month rates of OS
were 94% and 99% (P = .17), respectively (Appendix Fig
A5, online only).
MRD Responses Modulate Patients’ Risks at Diagnosis
The observed reduction in the risk of progression or death
observed in the intent-to-treat population with undetectable
MRD was consistent across all patients, including those
with high-risk cytogenetics (Fig 3; Appendix Table A6,
online only). The reduction in the risk of progression or
death also was evident in patients with elevated LDH levels;
however, probably because of its association with extra-
medullary disease, the HR was higher when compared with
patients who had normal LDH (0.47 v 0.18, respectively).
Similar results were observed with regard to OS (Appendix
Fig A6, online only).
When combining all risk parameters for the R-ISS
according to the IMWG guidelines (prognostic value of the
R-ISS is listed in Appendix Table A7, online only), there
were no significant differences in the 36-month PFS rate for
patients with R-ISS-I, R-ISS-II, or R-ISS-III statuses if MRD
was undetectable after treatment (95%, 94%, and 88%,
respectively; Fig 4A). Thus, patients with R-ISS-III status
had their poor prognoses overcome through the achieve-
ment of undetectable MRD. By contrast, outcomes were
progressively poor for patients with R-ISS-I, R-ISS-II, and
R-ISS-III statuses when MRD remained positive (36-month
PFS rates of 62%, 53%, and 28%, respectively; Fig 4B).
Similar results were observed when OS was considered
(Appendix Fig A7, online only). In Cox regression models
with forward selection, undetectable MRD was selected in
the first regression as the variable with the highest pre-
dictive value for PFS (HR, 0.12; 95% CI, 0.07 to 0.21;
P , .001) and OS (HR, 0.09; 95% CI, 0.04 to 0.23;
P, .001). In a second regression, both the R-ISS andMRD
statuses showed significant predictive values (Table 1).
Impact of Maintenance Therapy on Patients’
MRD Statuses
Overall, patient MRD status after consolidation remained
stable during the first 2 years of maintenance: approxi-
mately half of patients (103 [45%] of 190) had sustained
undetectable MRD, and one fifth (40 [21%] of 190) had
persistent MRD. Conversions from positive to negative MRD
during maintenance were observed in 33 (17%) of 190
patients, whereas the remaining 14 (7%) of 190 patients
lost the negative MRD status (Appendix Table A8, online
only). Longitudinal analysis of patients with paired MRD
assessment from consolidation into the first and second
years of maintenance denoted that most conversions from
MRD positive to negative status were achieved during the
first year.
DISCUSSION
The triple combination of proteasome inhibitors, immu-
nomodulatory agents, and corticosteroids is emerging as
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a standard of care for patients with MM.39-41 Based on
Cassiopeia,42 the efficacy of this triplet can be increased by
adding anti-CD38 monoclonal antibodies. Here, in a pro-
spective study with limited missing MRD data, we report
that a VRD/ASCT/VRD treatment scheme provides almost
50% MRD-negative rates; with a median follow-up of 40
months, patients with undetectable MRD after consolida-
tion showed very low risk of disease progression (7%), with
3-year survival rates reaching 90%. These are un-
precedented results that identify new outcomes for
transplant-eligible patients and establish undetectable
MRD as the new treatment end point for MM.
Despite the positive results accumulated in the past
decade,22,23 MRD assessment has been considered in MM
an exploratory test without clinical implications. Thus, MRD
has been valuable to identify a false CR (ie, patients in CR
with similar outcome to those in partial response because of
persistent MRD),15 but the achievement of undetectable
MRD using low-sensitive methods was associated with
a reduction in the risk of progression or death of only
60%.15 Here, we show that an MRD-negative response
defined by NGF identifies a group of patients with signif-
icantly lower risk of progression when compared with
previous studies using flow cytometry.5,6,12,13,15,16,18,40
Thus, our prospective analysis conducted in a large se-
ries of homogeneously treated patients validates the IMWG
flow MRD-negative response criterion and supports its
translation from trials into clinical practice. Of note, MRD
assessment in trials typically is performed at predefined
timepoints and irrespective of depth of response to prevent
missing data. Accordingly, some patients in less than CR
had undetectable MRD at a given timepoint, but most
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No. at risk No. at risk
FIG 4. Modulating patients’ risk at diagnosis according to depth of response after treatment, defined by measurable residual disease (MRD)
status. Impact on progression-free survival of the Revised International Staging System (R-ISS) in patients with (A) undetectable v (B) persistent MRD.
Of note, ISS was unavailable in six of 458 patient cases, lactate dehydrogenase in 19 of 458, and fluorescence in situ hybridization in 68 of 458.
HR, hazard ratio.
TABLE 1. Multivariable Analyses of PFS and OS, Incorporating Risk Stratification at Baseline According to the Revised International Staging
System and Response Assessment After Treatment According to MRD status
Model
PFS OS
HR 95% CI P HR 95% CI P
First regression
Undetectable v persistent MRD 0.12 0.07 to 0.21 , .001 0.09 0.04 to 0.23 , .001
Second regression
Undetectable v persistent MRD 0.12 0.07 to 0.21 , .001 0.09 0.04 to 0.23 , .001
R-ISS I/II v III 0.46 0.26 to 0.80 .006 0.29 0.15 to 0.55 , .001
Abbreviations: HR, hazard ratio; MRD, measurable residual disease; OS, overall survival; PFS, progression-free survival; R-ISS, Revised
International Staging System.
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practice, MRD should be performed whenever patients
achieve CR.
Despite the increased sensitivity of next-generation tech-
niques, some patients with undetectable MRD develop
early progression.20,27,34,36 Here, we show that approxi-
mately half of these patients, some of them with extra-
osseous plasmacytomas at diagnosis, presented new
plasmacytomas as an isolated criterion of disease pro-
gression without detectable M-protein or BM infiltration.
Thus, it appears that these were true false-negative MRD
results, reinforcing the need to combine NGF or NGS with
PET/CT to monitor treatment efficacy,25,30 particularly in
patients presenting with extramedullary or macrofocal
disease as well as elevated LDH levels.
After the promising results reported by Martinez-Lopez et al,20
subsequent studies21,27,31-34 confirmed the prognostic value of
NGS-based MRD assessment in MM and established it as the
gold standard amongmolecular methods to evaluate treatment
efficacy in this disease. Because the clinical meaning of
persistent MRD , 1025 remained uncertain, some studies
used an LOD of 1025 to define negative MRD,20,31-33 while
others adopted an LOD of 1026.21,34 Although, for prognostic
purposes, the IMWG threshold of , 1025 is adequate, our
study extends the findings by Perrot et al34 and Flores-Montero
et al36 and supports a negative MRD defined with an
LOD of 1026.
Based on low-sensitive flow cytometry, we and others re-
ported that patients who achieved MRD negativity after
induction had superior outcomes compared with patients
who achieved this response after HDT/ASCT,5,16 probably
because of the inability of these methods to detect MRD
, 0.01%.20,34,36 Here, we showed that, using sensitive
NGF, patients with undetectable MRD before or after HDT/
ASCT had virtually identical survival. These results, ob-
tained with a sequential scheme, suggest that persistent
MRD after induction may be used as an indication for early
intensification. Whether patients with undetectable MRD
after induction are candidates to harvest stem cells for
a late ASCT after disease progression (or, eg, MRD
reappearance) should be investigated in randomized
clinical trials. In addition, 17% of patients converted from
detectable to undetectable MRD during maintenance,
most of them in the first year. This rate is lower than in other
trials (eg, Myeloma XI, EMN02, BMT CTN 0702), which
could be related to exposure to lenalidomide during in-
duction/consolidation, which would render patients less
sensitive during maintenance, and/or to the higher sensi-
tivity of NGF versus less-sensitive flow cytometry assays
used in those studies. Of note, none of the patients con-
verting from detectable to undetectable MRD during
maintenance have experienced progression thus far, which
strengthens the clinical value of maintenance therapy.
In 2015, the IMWG developed the R-ISS to effectively risk
stratify patients on the basis of three diagnostic parame-
ters.43 Here, we show that achieving undetectable MRD by
NGF overcame the poor prognosis of adverse factors
identified at diagnosis, including high-risk cytogenetics.
This unveils that risk is dynamic, because patients with
adverse prognoses may shift into a favorable one upon
achieving deep responses to treatment. The opposite also
holds true; patients with R-ISS-I or R-ISS-II statuses and
detectable MRD have a PFS closer to that of patients with
R-ISS-III status and persistent MRD, rather than the other
patients with R-ISS-I or R-ISS-II statuses with undetectable
MRD. These results underline that MRD assessment helps
resolve the variability in patient survival predicted by the
R-ISS and highlight the value of the R-ISS to predict early
versus late disease progression in patients with detectable
MRD. Accordingly, patients with R-ISS-III status and per-
sistent MRD showed median PFS and OS times of only 14
and 17 months, respectively. This observation is clinically
meaningful, because these patients should be offered al-
ternative treatment strategies before insurmountable dis-
ease progression occurs. In conclusion, the IMWG flow
MRD-negative response criterion assessed in the BM is
highly applicable and sensitive to evaluate treatment effi-
cacy in MM.
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Miguel, Juan-José Lahuerta
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APPENDIX
List of Investigators in the GEM (Grupo Español de
Mieloma)/PETHEMA (Programa para el Estudio de la
Terapéutica en Hemopatı́as Malignas) Cooperative Study
Group
The following are study group investigators and locations: Dr. Marı́a
Casanova Espinosa, Complejo Hospitalario Costa del Sol; Dr. José Luı́s
Guzman Zamudio, H. Especialidades de Jerez de la Frontera; Dr.
Eduardo Rı́os Herranz, H. Nuestra Señora de Valme; Dr. Rafael Rios
Tamayo, H. Universitario Virgen de las Nieves; Dr. Jesús Martı́n
Sánchez, Complejo Hospitalario Regional Virgen del Rocı́o; Dr. Luı́s
Palomera Bernal, H. Clı́nico Universitario Lozano Blesa; Dr. Ana Pilar
González Rodrı́guez, H. Universitario Central de Asturias; Dr. Marı́a
Esther González Garcı́a, H. Cabueñes; Dr. Antonia Sampol Mayol,
Complejo Asistencial Son Espases; Dr. Joan Bargay Lleonart, H. Son
Llátzer; Dr. Alexia Suárez, H. de Gran Canaria Dr. Negrı́n; Dr. Miguel
Teodoro Hernández Garcı́a, H. Universitario de Canarias; Dr. Carmen
Montes Gaisán, H. Universitario Marqués de Valdecilla; Dr. Belén
Hernández Ruiz, H. General de Ciudad Real; Dr. Felipe Casado
Montero, Complejo Hospitalario de Toledo; Dr. Dunia de Miguel
Llorente, H. Universitario de Guadalajara; Dr. Fernando Solano
Ramos, H. Nuestra Señora del Prado (Talavera); Dr. Ángela Ibañez
Garcia, H. General de Albacete; Dr. Marivı́Mateos Manteca, H. Clı́nico
de Salamanca; Dr. José Mariano Hernández Martı́n, Complejo Hos-
pitalario H. General de Segovia; Dr. Fernando Escalante Barrigón,
H. de León; Dr. Javier Garcı́a Frade, H. Universitario Rio Hortega; Dr.
Alfonso Garcı́a de Coca, H. Clı́nico Universitario de Valladolid; Dr.
Carlos Aguilar Franco, H. Santa Bárbara; Dr. Jorge Labrador Gómez,
Hospital Universitario de Burgos; Dr. Elena Cabezudo Pérez, H.
Althaia, Xarxa Asistencial de Manresa (Sant Joan de Deu); Dr. Joan
Bladé Creixentı́, H CLINIC; Dr. Ana Ma Sureda Balari, H. Durán i
Reynals—ICO ĹHospitalet; Dr. Yolanda González Montes, ICO Girona,
H. Universitario de Girona Dr. Josep Trueta; Dr. Lourdes Escoda
Teigell, H. Universitario Joan XXII de Tarragona; Dr. Antonio Garcı́a
Guiñón, Hospital Universitari Arnau de Vilanova de Lleida; Dr. Eugenia
Abella Monreal, H. del Mar; Dr. Juan Alfonso Soler Campos, H. de
Sabadell (Parc Taulı́); Dr. Josep Ma Martı́ Tutusaus, Hospital Uni-
versitario Mútua de Terrassa; Dr. Albert Oriol Rocafiguera, H. Germans
Trias i Pujol; Dr. Miquel Granell Gorrochategui, H. de la Santa Creu i
Sant Pau; Dr. Mercedes Gironella Mesa, H. Vall d9Hebrón; Dr. Carmen
Cabrera Silva, H. San Pedro de Alcántara (Complejo Hospitalario de
Cáceres); Dr. Marta Sonia González Pérez, Complejo Hospitalario
Universitario de Santiago; Dr. Ana Dios Loureiro, Complejo Hospitalario
de Pontevedra; José Angel Méndez Sánchez, Complejo Hospitalario de
Ourense; Dr. Marı́a Josefa Nájera Irazu, H. San Pedro; Dr. Francisco
Javier Peñalver Párraga, H. Universitario Fundación de Alcorcón; Dr.
Juan José Lahuerta Palacios, H. Universitario 12 de Octubre; Dr. Pilar
Bravo Barahona, H. de Fuenlabrada; Dr. Cristina Encinas Rodrı́guez,
H. General Universitario Gregorio Marañón; Dr. José Ángel Hernández
Rivas, H. Infanta Leonor; Dr. Jaime Pérez de Oteyza, H. Universitario
Madrid—Sanchinarro; Dr. Rebeca Iglesias del Barrio, Centro
Oncológico MD Anderson; Dr. Ana López de la Guia, H. Universitario
La Paz; Dr. Adrián Alegre Amor, H. Universitario de la Princesa; Dr.
Elena Prieto Pareja, Fundación Jiménez Dı́az—UTE; Dr. Isabel Krsnik
Castelló, Hospital Universitario Puerta de Hierro—Majadahonda; Dr.
Ma Jesús Blanchard Rodrı́guez, H. Ramón y Cajal; Dr. Rafael
Martı́nez, H. Universitario de San Carlos; Dr. Rosalı́a Riaza Grau, H.
Severo Ochoa; Dr. Eugenio Giménez Mesa, H. Infanta Sofı́a; Dr. Elena
Ruiz Sainz, Hospital del Tajo; Dr. Felipe de Arriba, H. Morales
Meseguer; Dr. Jose Marı́a Moraleda Jiménez, H. Universitario Virgen
de la Arrixaca; Dr. Marta Romera, H. General Universitario Santa Lucia;
Dr. Felipe Prósper Cardoso, Clı́nica Universidad de Navarra; Dr. José
Ma Arguiñano Pérez, Complejo Hospitalario de Navarra; Dr. Marı́a
Puente Pomposo, H. de Cruces; Dr. Ernesto Pérez Persona, H. de
Txagorritxu; Dr. Ana Isabel Teruel Casasús, H. Clı́nico Universitario de
Valencia; Dr. Paz Ribas Garcı́a, H. Universitario Dr. Peset; Dr. Isidro
Jarque Ramos, H. Universitario La Fe; Dr. Marı́a Blanca Villarrubia Lor,
H. General Universitario de Alicante; Dr. Pedro Luis Fernández Garcı́a,
H. Torrevieja Salud UTE; and Dr. Pedro Luis Fernández Garcı́a, H. del
Vinalopo.
Supplementary Methods
Secondary end points of the PETHEMA/GEM2012MENOS65
clinical trial. The following were secondary end points:
• Complete response (CR) rates with negative immunofixation
after each phase of treatment (induction, autologous stem-cell
transplantation [ASCT] and consolidation);
• Measurable residual disease (MRD) in patients with immu-
nofixation-negative CR and after each phase of treatment
(induction, autologous stem-cell transplantation, and
consolidation);
• Overall survival after ASCT with busulfan + melphalan versus
melphalan; and
• Safety and tolerability of induction and consolidation
treatments.
Next-generation flow. MRD was assessed using the next-
generation flow (NGF) method developed by EuroFlow for highly
sensitive and standardized MRD detection in multiple myeloma
(Sanoja-Flores L, et al: Blood Cancer J 8:117, 2018).36 In brief, the
method is based on a (standardized) lyse-wash-and-stain protocol and
an optimized eight-color, two-tube antibody panel for accurate iden-
tification of phenotypically aberrant, clonal plasma cells (PCs): Tube 1
includes CD138-BV421, CD27-BV510, CD38-FITC, CD56-PE, CD45-
PerCPCy5.5, CD19-PECy7, CD117-APC, and CD81-APCH7; tube 2
includes CD138-BV421, CD27-BV510, CD38-FITC, CD56-PE, CD45-
PerCPCy5.5, CD19-PECy7, cyKAPPA-APC, and cyLAMBDA-APCH7
(Arana P, et al: Leukemia 32:971-978, 2018).36 The two-tube strategy
allows detection of MRD with specific confirmation of light-chain
(mono)clonality on phenotypically aberrant PCs, identified by anti-
gen underexpression (CD19, CD27, CD38, CD45, CD81) or over-
expression (CD56, CD117, CD138) compared with normal PCs (Arana
P, et al: Leukemia 32:971-978, 2018).36 Data acquisition was per-
formed in a FACSCanto II flow cytometer (BD, San Jose, CA) using the
FACSDiva 6.1 software (BD). Data analysis was performed by expe-
rienced operators using the Infinicyt software (Cytognos SL, Sala-
manca, Spain). MRD assessments were performed blinded for clinical
outcomes in three PETHEMA/GEM laboratories and data were cen-
tralized for MRD analyses.
Cytogenetic characterization. Fluorescence in-situ hybridization
was performed at diagnosis in the same three PETHEMA/GEM labo-
ratories that perform MRD monitoring. Immunomagnetically enriched
PCs from 390 of 458 patients were tested for chromosome 1 alter-
ations, IGH translocations and del(17p13). Patients with t(4;14), t(14;
16), and/or del(17p13) were classified as high risk (n = 90); others
were classified as standard risk (n = 300).
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FIG A1. Schema of the PETHEMAGEM2012MENOS65 (in light blue) andGEM2014MAIN trials (in light red). Bu-Mel, busulfan +melphalan; d, low-
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Undetectable MRD; CIR at 3 years, 10%
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FIG A2. (A) Kaplan-Meier estimates of time-to progression (TTP), defined as the time from measurable residual disease (MRD) assessment until disease
progression, according to patients’ MRD statuses after consolidation (n = 357). Data from patients who died in the absence of progression were thus
censored. The 3-year TTP rates were 89% v 51% for patients with undetectable v persistent MRD, respectively. (B) The cumulative incidence of relapse (CIR)
was calculated from the time fromMRD assessment to the date of disease progression, considering death without disease progression as a competing event.
HR, hazard ratio.
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FIG A3. Survival according to undetectable v persistent measurable residual disease (MRD) in patients in complete remission (CR) after con-
solidation. (A) The Kaplan-Meier estimate of the 36-month progression-free survival (PFS) rate was 85% v 24% in patients with undetectable v
persistent MRD. (B) The 36-month overall survival (OS) rate was 96% v 89% in patients with undetectable v persistent MRD. HR, hazard ratio.
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FIG A4. Progression-free survival (PFS) according to the presence of undetectable v persistent
measurable residual disease (MRD) in the logarithmic ranges of $ 2 3 1026 to , 1025, $ 1025 to
, 1024 and $ 1024 after consolidation (n = 357). All pairwise comparisons between patients with
negative v positive MRD in in the logarithmic ranges of $ 2 3 1026 to , 1025, $ 1025 to , 1024 and
$ 1024 were statistically significant (P , .001). By contrast, there were no statistically significant
differences in PFS of patients with positive MRD in the logarithmic range of $ 2 3 1026 to , 1025 v
those with MRD levels of$ 1025 to, 1024 or v those with MRD$ 1024. There were also no statistically
significant differences when comparing the PFS of patients withMRD in the logarithmic range of$ 1025
to , 1024 v those with MRD $ 1024.
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Persistent MRD; median PFS, 36 months
FIG A5. Progression-free survival (PFS) after consolidation (n = 357) according to the moment at which
measurable residual disease (MRD) is undetectable: after induction v after intensification (either after
high-dose therapy or consolidation). Data from patients with persistent MRD across the entire duration
of the study were also plotted. Of note, 16 patients achieved negativeMRD after induction (n = 1) or after
high-dose therapy/autologous stem-cell transplantation (n = 15) but lost their MRD-negative status at
the end of consolidation; five of the 16 experienced disease progression.
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FIG A6. Subgroup analysis of overall survival according to patients’ time-dependent measurable residual disease
status. The intent-to-treat patient population was subgrouped according to sex, age, International Staging System
(ISS), lactate dehydrogenase (LDH) levels, and cytogenetic alterations. (*) No events in this subgroup category.
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R-ISS-I v R-ISS-II: HR, 2.56; 95% CI, 1.14 to 5.70; P = .022
R-ISS-I v R-ISS-III: HR, 2.78; 95% CI, 1.72 to 4.46; P < .001
R-ISS-II v R-ISS-III: HR, 3.03; 95% CI, 1.55 to 5.93; P = .001
FIG A7. Modulating patients’ risks at diagnosis according to depth of response after treatment, defined by measurable residual disease (MRD)
status. Impact on overall survival (OS) of the Revised International Staging System (R-ISS) in patients with (A) undetectable v (B) persistent
measurable residual disease. The Kaplan-Meyer OS curves of patients with R-ISS-I and -III are superimposed, because no events were observed
in either patient subgroup. HR, hazard ratio.
TABLE A1. Longitudinal MRD Response Rates After Induction, HDT/ASCT, and
Consolidation in the Intent-to-Treat Patient Population Enrolled in the
GEM2012MENOS65 Clinical Trial
MRD Status
No. (%) of Occurrences by Phase of
Therapy (N = 458)
VRD 3 6 HDT/ASCT VRD 3 2
On intent-to-treat protocol (n = 458)
Undetectable MRD 129 (28) 194 (42) 208 (45)
Persistent MRD 329 (72) 264 (58) 250 (55)
MRD log levels $ 1024 244 (74) 170 (64) 156 (63)
MRD log levels $ 1025 and , 1024 66 (20) 73 (28) 46 (18)
MRD log levels $ 2 3 1026 and 1025 19 (6) 21 (8) 48 (19)
Longitudinally (n = 317)
Undetectable MRD 110 (35) 173 (55) 185 (58)
Persistent MRD 207 (65) 144 (45) 132 (42)
MRD log levels $ 1024 139 (67) 61 (42) 47 (36)
MRD log levels $ 1025 and , 1024 52 (25) 65 (45) 42 (32)
MRD log levels $ 2 3 1026 and 1025 16 (8) 18 (13) 43 (32)
NOTE. Three hundred seventeen patients had MRD assessed at all three
timepoints, and results for this cohort are shown in the lower part of the Table.
Patients with MRD-positive statuses were subgrouped according to detectable
MRD log levels to evaluate the impact of different treatment stages in persistent
MRD.
Abbreviations: HDT/ASCT, high-dose therapy followed by autologous stem-cell
transplantation; MRD, measurable residual disease; VRD 3 2, consolidation
therapy; VRD 3 6, induction therapy.
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TABLE A2. MRD Status Assessed After Induction, HDT/ASCT, and Consolidation in the GEM2012MENOS65 Clinical Trial According to Conventional
Response Criteria
MRD Status
No. (%) of Occurrences by Treatment Stage























































NOTE. Conventional response criteria used: CR, VGPR, and # PR. The numbers of patients in CR, VGPR, and # PR after induction, HDT/ASCT, and
consolidation are reported for the cohort of patients with MRD assessment at that specific treatment stage.
Abbreviations: CR, complete remission; HDT/ASCT, high-dose therapy followed by autologous stem-cell transplantation; MRD, measurable residual
disease; # PR, partial response or less; VGPR, very good partial response.





















1 III Normal SR No (PET/CT) sCR IND 1026 51 Yes 40 100 No (PET/CT)
2 I Elevated HR No (CT, MRI) sCR CONS 1026 46 Yes 2 0 No (CT, MRI)
3 II Normal SR Yes (PET/CT) VGPR IND 1026 20 No 4 0 Yes (PET/CT)
4 I Normal SR No (WB-MRI) sCR HDT 1026 44 Yes 36 28 No (WB-MRI)
5 III Elevated HR Yes (PET/CT) sCR IND 1026 28 No 3 0 Yes (PET/CT)
6 II Normal SR No (WB-MRI) sCR IND 1026 43 No 0.2 0 Yes (PET/CT)
7 I Normal SR Yes (PET/CT) sCR IND 1025 36 No 2 0 Yes (PET/CT)
8 II Normal SR No (PET/CT) CR CONS 1026 34 Yes NE NE NE
9 III Normal TF No (x-rays, CT) sCR HDT 1026 35 Yes 17 100 NE
10 I Normal SR No (CT) sCR CONS 1026 36 No 2 86 Yes (CT)
11 III Elevated SR Yes (PET/CT) sCR IND 1026 25 No 1 0 Yes (PET/CT)
12 I Normal TF No (PET/CT) sCR IND 1026 33 No 5 50 No (PET/CT)
13 I Normal TF NE (x-rays) CR CONS 1026 20 No 58 100 NE
14 III Elevated SR Yes (PET/CT) sCR IND 1026 27 No 1 0 No* (PET/CT)
NOTE. The incidence of +1q (7/14) was higher than that typically observed in newly-diagnosed multiple myeloma (approximately 30%).
Abbreviations: BM PCs, bone marrow plasma cells; CONS, consolidation; CR, complete response; CT, computed tomography; FISH, fluorescence in situ
hybridization; HDT, high-dose therapy; HR, high risk [t(4;14), t(14;16) and/or del(17p)]; IND, induction; ISS, International Staging System; LDH, lactate
dehydrogenase; LOD, limit of detection achieved at the time of the latest MRD assessment; MRD, measurable residual disease; MRI, magnetic resonance
imaging; NE, not evaluated; PCs, plasma cells; PET, positron emission tomography; sCR, stringent CR; SR, standard risk; TF, test failure; VGPR, very good
partial response; WB-MRI, whole-body MRI.
*Multifocal disease.
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TABLE A4. PFS and OS of Patients With Undetectable MRD
Conditioned With Bu-Mel or Mel-200 High-Dose Therapy
Survival Type







36-month PFS 88 86 .61
36-month OS 98 95 .38
NOTE. Achieving undetectable MRD before maintenance was
associated with a 77% reduction in the risk of progression or death
(HR, 0.23; P , .001) in patients treated with Bu-Mel and an 81%
reduction (HR, 0.19; P , .001) in patients treated with Mel-200
high-dose therapy.
Abbreviations: Bu-Mel, busulfan + melphalan; HR, hazard ratio;
Mel, melphalan; MRD, measurable residual disease; OS, overall
survival; PFS, progression-free survival.
TABLE A5. PFS and OS of Patients With Undetectable MRD Receiving
Maintenance With RD or IRD
Survival Type







36-month PFS 86 90 .50
36-month OS 98 94 .18
NOTE. Achieving undetectable MRD before maintenance was
associated with a 77% reduction in the risk of progression or death
(HR, 0.23; P , .001) in patients treated with IRD and an 80%
reduction (HR, 0.20; P = .001) in patients treated with RD.
Abbreviations: HR, hazard ratio; IRD, RD + ixazomib; MRD,
measurable residual disease; OS, overall survival; PFS,
progression-free survival; RD, lenalidomide + dexamethasone.
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TABLE A6. Subgroup Analysis of Disease Progression Rates
According to Patients’ Time-Dependent MRD Statuses
Subgroup No. of Patients
No. (%) of Progressions/No. of
Patients by MRD Status
Undetectable Persistent
Sex
Male 239 8 (8)/103 55 (40)/136
Female 218 6 (6)/101 46 (39)/117
P .78 .90
Age, years
# 55 175 4 (6)/72 35 (35)/103
. 55 282 10 (8)132 66 (44)/150
P .77 .12
ISS
I 179 6 (7)/85 29 (31)94
II 164 2 (3)/73 41 (45)91
III 108 6 (14)/44 30 (47)/64
P .08 .06
LDH
Normal 373 10 (6)/178 75 (39)/195
Elevated 70 4 (22)/18 23 (48)/48
P .03 .25
Cytogenetics
Standard risk 300 9 (7)/136 56 (34)/164
High risk 90 2 (6)/32 34 (59)/58
Test failure 69 3 (8)/37 11 (36)/31
P .94 .004
NOTE. The intent-to-treat patient population was subgrouped
according to sex, age, ISS, LDH levels, and cytogenetic abnormalities.
Abbreviations: ISS, International Staging System; LDH, lactate
dehydrogenase; MRD, measurable residual disease.
TABLE A7. Multivariable Analyses of PFS and OS According to the R-ISS
R-ISS Subgroup
PFS OS
Median (months) 36-Month Rate (%) P Median (months) 36-Month Rate (%) P
I NR 77 NR 94
II NR 70 .002 NR 83 , .001
III 28 46 NR 58
Abbreviations: NR, not reached; OS, overall survival; PFS, progression-free survival; R-ISS, Revised International Staging System.
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TABLE A8. Impact of Maintenance Therapy on Patients’ MRD
Statuses
MRD Status







MRD2 → MRD2 107 (56.3) 123 (64.7) 103 (54.2)
MRD+ → MRD2 33 (17.4) 13 (6.8) 33 (17.4)
MRD2 → MRD+ 10 (5.3) 17 (8.9) 14 (7.4)
MRD+ → MRD+ 40 (21.1) 37 (19.5) 40 (21.1)
NOTE. According to the GEM2014MAIN study design, MRD was
assessed every year duringmaintenance. The longitudinal comparison
from CONS into M1 and M2 was performed in the 190 patients with
MRD assessment at all three timepoints. Results also are reported for
the paired comparison between CONS and M1 (CONS→M1) and the
paired comparison between M1 and M2 (M1→M2). Patients were
categorized into sustained MRD negativity from consolidation to
maintenance (MRD2 →MRD2), conversion from MRD+ into MRD2
during maintenance (MRD+→MRD2), loss of MRD negativity during
maintenance (MRD2 → MRD+), and persistent MRD from
consolidation to maintenance (MRD+ → MRD+). Of note, none of the
patients who converted from MRD+ into MRD2 during maintenance
or who lost their MRD negativity duringmaintenance have experienced
disease progression thus far.
Abbreviations: +, positive; 2, negative; CONS, consolidation; M1,
first year of maintenance; M2, second year of maintenance; MRD,
measurable residual disease.
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